Mission Biocapital — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
BiotechCambridge, US
Livio Valenti(Executive Officer)Kathryn Kosuda(Executive Officer, Director)Michael Schrader(Executive Officer, Director)Matthew Dirckx(Executive Officer)Lynda Tussey(Executive Officer)John Spiridigliozzi(Executive Officer)
Board seatJohannes Fruehauf· per SEC Form D
Co-investorsGlobal Health Investment CorporationRA Capital
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital HealthMedford, US
Jerrold Rosenbaum(Director)inJacob Hooker(Executive Officer, Director)inPranav Tadi(Executive Officer)
BoardRyan Katz(Director)inKevin Lalande(Director)inRichard Simon(Director)
Co-investorsBonaventure Equity, LLCHatteras Venture PartnersIter InvestmentsRoute 66 VenturesService Provider CapitalSante Health Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.